Maria J. Bueno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria J. Bueno has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Miguel Quintela-Fandino
Breast Cancer Clinical Research Unit, Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spain
15 shared publications - Jose Angel Garcia Saenz
GEICAM, Spanish Breast Cancer Group, Madrid, Spain
14 shared publications - Luis Manso
Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
14 shared publications - Silvana Mourón
Spanish National Cancer Research Centre, Madrid, Spain
13 shared publications - Alfonso Cortés-Salgado
Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; Universidad de Alcalá, Medical Oncology Department, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain
9 shared publications - Juan Antonio Guerra
Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain
9 shared publications
Latest Publications
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Representativeness of Study Participants table
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Representativeness of Study Participants table
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Trial schedule and CONSORT diagram. A, Basic trial schedule. Prescreened patients positive for either p-ERK and/or CDK6 were eligible after experiencing RECIST v1.1 disease progression to their first or second treatment line for advanced disease. Treatment consisted of continuous binimetinib (45 mg orally twice a day) and palbociclib (100 mg/day, orally) from days 1 to 21 of 28-day cycles. Palbociclib was allowed to be escalated to 125 mg/day in case of patients showing acceptable tolerance to 100/day during cycle 1. Treatment continued until disease progression, unacceptable toxicity, or investigator decision. D, day. B, CONSORT diagram. * The most frequent reasons for not meeting inclusion criteria were having received less than one or more than two treatment lines for advanced TNBC (n = 9), not having experienced disease progression to the previous treatment line according to RECIST v1.1 (n = 9), and inadequate organ function (n = 2). Eval., evaluation.
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Trial schedule and CONSORT diagram. A, Basic trial schedule. Prescreened patients positive for either p-ERK and/or CDK6 were eligible after experiencing RECIST v1.1 disease progression to their first or second treatment line for advanced disease. Treatment consisted of continuous binimetinib (45 mg orally twice a day) and palbociclib (100 mg/day, orally) from days 1 to 21 of 28-day cycles. Palbociclib was allowed to be escalated to 125 mg/day in case of patients showing acceptable tolerance to 100/day during cycle 1. Treatment continued until disease progression, unacceptable toxicity, or investigator decision. D, day. B, CONSORT diagram. * The most frequent reasons for not meeting inclusion criteria were having received less than one or more than two treatment lines for advanced TNBC (n = 9), not having experienced disease progression to the previous treatment line according to RECIST v1.1 (n = 9), and inadequate organ function (n = 2). Eval., evaluation.
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Efficacy results. A, Kaplan–Meier (KM) curve and (B) swimmer plot displaying PFS time for the efficacy population (N = 23). C, Waterfall plot showing the best overall response for the 16 patients with measurable disease. The mutational status of the most frequently mutated genes in TNBC is shown underneath the waterfall plot. D, Spider plot of the efficacy population.
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Efficacy results. A, Kaplan–Meier (KM) curve and (B) swimmer plot displaying PFS time for the efficacy population (N = 23). C, Waterfall plot showing the best overall response for the 16 patients with measurable disease. The mutational status of the most frequently mutated genes in TNBC is shown underneath the waterfall plot. D, Spider plot of the efficacy population.
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Data from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Purpose:Advanced, pretreated triple-negative breast cancer (TNBC) has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that cyclin-dependent kinase 6 (CDK6) and ERK hyperactivation are linked to adverse outcomes and represent actionable targets. This prompted us to evaluate palbociclib and binimetinib in advanced TNBC after one or two prior therapies.Patients and Methods:Patients with increased ERK and/or CDK6 activity were eligible. Treatment consisted in daily binimetinib (45 mg twice a day) plus palbociclib (100 mg daily, days 1–21) in 28-day cycles. Palbociclib escalation to 125 mg was allowed in cycle 2. The primary objective was to demonstrate a 2.5 month–long progression-free survival (PFS), a 50% increase over the reference PFS for cytotoxics (1.7 months). Whole-exome sequencing was performed in tumor samples of the efficacy population.Results:Fifty-one patients were screened, of whom 50 were biomarker-positive. Twenty-four initiated treatment between June 2021 and July 2022. Toxicity was frequent, consisting mainly in fatigue, diarrhea, neutropenia, and ocular effects, requiring frequent dose interruptions or reductions. The primary objective was not met (median PFS 50 days). However, a bimodal PFS pattern emerged, with 13% of the patients achieving disease control lasting 4 to 13 months. Whole-exome sequencing revealed a distinct mutational landscape among long-term responders compared with early progressors.Conclusions:In this biomarker-enriched TNBC population, the combination of palbociclib and binimetinib showed limited activity and notable toxicity. Whereas CDK6 and ERK hyperactivation confirmed their prognostic role, they did not predict treatment benefit. Exploratory genomic findings suggest the existence of a biologically distinct subset of patients with prolonged benefit, encouraging further investigation.Significance:Previous studies showed that patients with early TNBC with increased CDK4/6 and ERK activity are at high risk of relapse. Preclinical data also suggest the benefit of combined inhibition of CDK4/6 and MEK, and novel therapies are needed for TNBC in the advanced disease setting. Despite the rationale and a biomarker-driven design, this combination was toxic and showed limited efficacy. This combination should not be further developed in this disease.
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Purpose:Advanced, pretreated triple-negative breast cancer (TNBC) has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that cyclin-dependent kinase 6 (CDK6) and ERK hyperactivation are linked to adverse outcomes and represent actionable targets. This prompted us to evaluate palbociclib and binimetinib in advanced TNBC after one or two prior therapies.Patients and Methods:Patients with increased ERK and/or CDK6 activity were eligible. Treatment consisted in daily binimetinib (45 mg twice a day) plus palbociclib (100 mg daily, days 1–21) in 28-day cycles. Palbociclib escalation to 125 mg was allowed in cycle 2. The primary objective was to demonstrate a 2.5 month–long progression-free survival (PFS), a 50% increase over the reference PFS for cytotoxics (1.7 months). Whole-exome sequencing was performed in tumor samples of the efficacy population.Results:Fifty-one patients were screened, of whom 50 were biomarker-positive. Twenty-four initiated treatment between June 2021 and July 2022. Toxicity was frequent, consisting mainly in fatigue, diarrhea, neutropenia, and ocular effects, requiring frequent dose interruptions or reductions. The primary objective was not met (median PFS 50 days). However, a bimodal PFS pattern emerged, with 13% of the patients achieving disease control lasting 4 to 13 months. Whole-exome sequencing revealed a distinct mutational landscape among long-term responders compared with early progressors.Conclusions:In this biomarker-enriched TNBC population, the combination of palbociclib and binimetinib showed limited activity and notable toxicity. Whereas CDK6 and ERK hyperactivation confirmed their prognostic role, they did not predict treatment benefit. Exploratory genomic findings suggest the existence of a biologically distinct subset of patients with prolonged benefit, encouraging further investigation.Significance:Previous studies showed that patients with early TNBC with increased CDK4/6 and ERK activity are at high risk of relapse. Preclinical data also suggest the benefit of combined inhibition of CDK4/6 and MEK, and novel therapies are needed for TNBC in the advanced disease setting. Despite the rationale and a biomarker-driven design, this combination was toxic and showed limited efficacy. This combination should not be further developed in this disease.
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Figure S1 shows CDK6 and p-ERK positivity in screened samples
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Figure S1 shows CDK6 and p-ERK positivity in screened samples
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Correlative studies. A, Dot plot showing the correlation between CDK6 and (B) p-ERK staining (Z-score) and PFS time. The Pearson coefficients were −0.158 (P = 0.472) and 0.143 (P = 0.514). C, Mutational status of HR genes among patients with short (4 months) progression-free interval. Dark color indicates WT status of both alleles; green indicates a heterozygous deleterious mutation, and yellow indicates deleterious alterations in both alleles. D, Heatmap depicting the genes with differential mutational pattern between patients with short or long PFS, listed by their T test score. Darker colors indicate none or lower number of deleterious mutations across their exome, whereas lighter colors indicate increased number of deleterious mutations (up to 5).
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Correlative studies. A, Dot plot showing the correlation between CDK6 and (B) p-ERK staining (Z-score) and PFS time. The Pearson coefficients were −0.158 (P = 0.472) and 0.143 (P = 0.514). C, Mutational status of HR genes among patients with short (4 months) progression-free interval. Dark color indicates WT status of both alleles; green indicates a heterozygous deleterious mutation, and yellow indicates deleterious alterations in both alleles. D, Heatmap depicting the genes with differential mutational pattern between patients with short or long PFS, listed by their T test score. Darker colors indicate none or lower number of deleterious mutations across their exome, whereas lighter colors indicate increased number of deleterious mutations (up to 5).
- Open Access
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Adverse events grade 2 or higher attributed to palbociclib and binimetinib (>5% of the patients).
- 29 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Adverse events grade 2 or higher attributed to palbociclib and binimetinib (>5% of the patients).
- Open Access
- 10 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 5 (9) , 1728-1737
A phase IB study of binimetinib and palbociclib in molecularly selected advanced triple-negative breast cancer.
Purpose:Advanced, pre-treated TNBC has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that CDK6 and ERK hyperactivation are linked to adverse outcomes and represent actionable targets. This prompted us to evaluate palbociclib and binimetinib in advanced TNBC after one or two prior therapies. Patients and Methods:Patients with increased ERK and/or CDK6 activity were eligible. Treatment consisted in daily binimetinib (45 mg BID) plus palbociclib (100 mg daily, days 1-21) in 28-day cycles. Palbociclib escalation to 125 was allowed in cycle 2. The primary objective was to demonstrate a 2.5 month-long PFS, a 50% increase over the reference PFS for cytotoxics (1.7 months). Whole-exome sequence (WES) was performed in tumor samples of the efficacy population. Results:Fifty-one patients were screened, 50 were biomarker-positive. Twenty-four initiated treatment between June 2021 and July 2022. Toxicity was frequent, consisting mainly in fatigue, diarrhea, neutropenia and ocular effects, requiring frequent dose interruptions or reductions. The primary objective was not met (median PFS 50 days). However, a bimodal PFS pattern emerged, with 13% of the patients achieving disease control lasting 4-13 months. WES revealed a distinct mutational landscape among long-term responders compared to early progressors. Conclusions:In this biomarker-enriched TNBC population, the combination of palbociclib and binimetinib showed limited activity and notable toxicity. While CDK6 and ERK hyperactivation confirmed their prognostic role, they did not predict treatment benefit. Exploratory genomic findings suggest the existence of a biologically distinct subset of patients with prolonged benefit, encouraging further investigation.
- 10 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 5 (9) , 1728-1737
Open AccessA phase IB study of binimetinib and palbociclib in molecularly selected advanced triple-negative breast cancer.
Purpose:Advanced, pre-treated TNBC has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that CDK6 and ERK hyperactivation are linked to adverse outcomes and represent actionable targets. This prompted us to evaluate palbociclib and binimetinib in advanced TNBC after one or two prior therapies. Patients and Methods:Patients with increased ERK and/or CDK6 activity were eligible. Treatment consisted in daily binimetinib (45 mg BID) plus palbociclib (100 mg daily, days 1-21) in 28-day cycles. Palbociclib escalation to 125 was allowed in cycle 2. The primary objective was to demonstrate a 2.5 month-long PFS, a 50% increase over the reference PFS for cytotoxics (1.7 months). Whole-exome sequence (WES) was performed in tumor samples of the efficacy population. Results:Fifty-one patients were screened, 50 were biomarker-positive. Twenty-four initiated treatment between June 2021 and July 2022. Toxicity was frequent, consisting mainly in fatigue, diarrhea, neutropenia and ocular effects, requiring frequent dose interruptions or reductions. The primary objective was not met (median PFS 50 days). However, a bimodal PFS pattern emerged, with 13% of the patients achieving disease control lasting 4-13 months. WES revealed a distinct mutational landscape among long-term responders compared to early progressors. Conclusions:In this biomarker-enriched TNBC population, the combination of palbociclib and binimetinib showed limited activity and notable toxicity. While CDK6 and ERK hyperactivation confirmed their prognostic role, they did not predict treatment benefit. Exploratory genomic findings suggest the existence of a biologically distinct subset of patients with prolonged benefit, encouraging further investigation.